108 related articles for article (PubMed ID: 15893177)
1. What promise does PCSK9 hold?
Kastelein JJ; Fouchier SW; Defesche JC
J Am Coll Cardiol; 2005 May; 45(10):1620-1. PubMed ID: 15893177
[No Abstract] [Full Text] [Related]
2. A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis.
Chen SN; Ballantyne CM; Gotto AM; Tan Y; Willerson JT; Marian AJ
J Am Coll Cardiol; 2005 May; 45(10):1611-9. PubMed ID: 15893176
[TBL] [Abstract][Full Text] [Related]
3. Beyond LDL cholesterol, a new role for PCSK9.
Akram ON; Bernier A; Petrides F; Wong G; Lambert G
Arterioscler Thromb Vasc Biol; 2010 Jul; 30(7):1279-81. PubMed ID: 20554949
[No Abstract] [Full Text] [Related]
4. Protease variants, LDL, and coronary heart disease.
Tall AR
N Engl J Med; 2006 Mar; 354(12):1310-2. PubMed ID: 16554535
[No Abstract] [Full Text] [Related]
5. [PCSK9 inhibitor is convincing a large analysis].
Schlimpert V
MMW Fortschr Med; 2015 Dec; 157(21-22):90. PubMed ID: 26960892
[No Abstract] [Full Text] [Related]
6. The associations between proprotein convertase subtilisin/kexin type 9 E670G polymorphism and the risk of coronary artery disease and serum lipid levels: a meta-analysis.
Cai G; Zhang B; Shi G; Weng W; Ma C; Song Y; Zhang J
Lipids Health Dis; 2015 Nov; 14():149. PubMed ID: 26576960
[TBL] [Abstract][Full Text] [Related]
7. The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population.
Hooper AJ; Marais AD; Tanyanyiwa DM; Burnett JR
Atherosclerosis; 2007 Aug; 193(2):445-8. PubMed ID: 16989838
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of PCSK9: is this the way forward for managing residual risk?
Chowdhury SR; Rees A
Curr Opin Lipidol; 2012 Oct; 23(5):509-10. PubMed ID: 22964999
[No Abstract] [Full Text] [Related]
9. [PCSK9: a new gene involved in familial hypercholesteremia].
Lambert G; Costet P; Krempf M; Lalanne F
Med Sci (Paris); 2004 Dec; 20(12):1068-70. PubMed ID: 15581455
[No Abstract] [Full Text] [Related]
10. Systematic analysis of variants related to familial hypercholesterolemia in families with premature myocardial infarction.
Brænne I; Kleinecke M; Reiz B; Graf E; Strom T; Wieland T; Fischer M; Kessler T; Hengstenberg C; Meitinger T; Erdmann J; Schunkert H
Eur J Hum Genet; 2016 Feb; 24(2):191-7. PubMed ID: 26036859
[TBL] [Abstract][Full Text] [Related]
11. Proprotein convertase subtilisin/kexin type 9, its variants and regulation of low-density lipoprotein cholesterol.
Wierzbicki AS
Curr Opin Lipidol; 2007 Apr; 18(2):227-9. PubMed ID: 17353672
[No Abstract] [Full Text] [Related]
12. Sorting the wheat from the chaff in familial hypercholesterolemia.
Hooper AJ; Watts GF
Clin Chem; 2015 Jan; 61(1):6-8. PubMed ID: 25391991
[No Abstract] [Full Text] [Related]
13. Molecular biology of PCSK9: its role in LDL metabolism.
Horton JD; Cohen JC; Hobbs HH
Trends Biochem Sci; 2007 Feb; 32(2):71-7. PubMed ID: 17215125
[TBL] [Abstract][Full Text] [Related]
14. The PCSK9 gene R46L variant is associated with lower plasma lipid levels and cardiovascular risk in healthy U.K. men.
Scartezini M; Hubbart C; Whittall RA; Cooper JA; Neil AH; Humphries SE
Clin Sci (Lond); 2007 Dec; 113(11):435-41. PubMed ID: 17550346
[TBL] [Abstract][Full Text] [Related]
15. [PCSK9 - break through in the prevention and treatment of arteriosclerosis?].
Lewartowski B
Kardiol Pol; 2009 Jul; 67(7):782-6. PubMed ID: 19650002
[No Abstract] [Full Text] [Related]
16. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia.
Abifadel M; Varret M; Rabès JP; Allard D; Ouguerram K; Devillers M; Cruaud C; Benjannet S; Wickham L; Erlich D; Derré A; Villéger L; Farnier M; Beucler I; Bruckert E; Chambaz J; Chanu B; Lecerf JM; Luc G; Moulin P; Weissenbach J; Prat A; Krempf M; Junien C; Seidah NG; Boileau C
Nat Genet; 2003 Jun; 34(2):154-6. PubMed ID: 12730697
[TBL] [Abstract][Full Text] [Related]
17. Characterization of the first PCSK9 gain of function homozygote.
Alves AC; Etxebarria A; Medeiros AM; Benito-Vicente A; Thedrez A; Passard M; Croyal M; Martin C; Lambert G; Bourbon M
J Am Coll Cardiol; 2015 Nov; 66(19):2152-2154. PubMed ID: 26541928
[No Abstract] [Full Text] [Related]
18. How does mutant proprotein convertase neural apoptosis-regulated convertase 1 induce autosomal dominant hypercholesterolemia?
Jirholt P; Adiels M; Borén J
Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):1334-6. PubMed ID: 15297286
[No Abstract] [Full Text] [Related]
19. The management of familial hypercholesterolaemia in Morocco.
El Messal M; Aït Chihab K; Chater R; Loutfi M; Kettani A; Hafidi A; Adlouni A
Acta Cardiol; 2006 Oct; 61(5):551-5. PubMed ID: 17117756
[TBL] [Abstract][Full Text] [Related]
20. [Effective LDL cholesterol reduction for high risk patients].
Einecke D
MMW Fortschr Med; 2016 Apr; 158(8):84. PubMed ID: 27116175
[No Abstract] [Full Text] [Related]
[Next] [New Search]
